Amgen gets boost from court ruling
The surprise verdict by a Chicago arbitration panel giving Amgen Inc. sole rights to a promising new drug is good news for the biotechnology company. The panel ruled that a next-generation anemia
The surprise verdict by a Chicago arbitration panel giving Amgen Inc. sole rights to a promising new drug is good news for the biotechnology company. The panel ruled that a next-generation anemia